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Abstract
Human cytomegalovirus (CMV) is a ubiquitous DNA virus that causes severe disease in patients with immature or
impaired immune systems. During active infection, CMV modulates host immunity, and CMV-infected patients
often develop signs of immune dysfunction, such as immunosuppression and autoimmune phenomena.
Furthermore, active viral infection has been observed in several autoimmune diseases, and case reports have linked
primary CMV infection and the onset of autoimmune disorders. In addition, CMV infection promotes allograft
rejection and graft-versus-host disease in solid organ and bone marrow transplant recipients, respectively, further
implicating CMV in the genesis and maintenance of immunopathological phenomena. The mechanisms by which
CMV could induce inhibition of host defense, inflammation, and autoimmunity are discussed, as is the treatment of
virus-induced immunopathology with antivirals.
Human cytomegalovirus
Human cytomegalovirus (CMV) is a widespread agent
that belongs to the Herpesviridae family [1]. Viral pro-
teins are expressed in the immediate early (IE), early (E),
and late (L) phases of CMV infection. Its genome con-
tains more than 200 potential reading frames from
which effector proteins can be generated, but merely
one-quarter is committed to replication [2,3]. Thus, the
majority of viral proteins potentially modulates cellular
responses in the host; of all herpesviruses, CMV
expresses the most genes that alter innate and adaptive
host immune responses [4].
During the acute phase of CMV infection, many cell
types in an organ system can be infected, including
endothelial cells, epithelial cells, smooth muscle cells,
fibroblasts, neuronal cells, hepatocytes, trophoblasts,
monocytes/macrophages (Mjs), and dendritic cells
(DCs) [5]. The virus typically is acquired early in life
and can be transmitted by direct or indirect contact
with infected body fluids. There are 3 forms of active
CMV infection: a) primary infection, which occurs when
the virus infects a CMV-naive host; b) endogenous
infection in CMV-seropositive individuals who experi-
ence reactivation from latency, and c) exogenous
reinfection in previously infected individuals who experi-
ence infection by a different strain [6].
Recent evidence shows that active and latent CMV
infection induces sustained systemic inflammatory
responses that are accompanied by a type 1 cytokine
signature [7]. Viral persistence is established in all
infected individuals and is chronically productive or
occurs as a latent infection in which viral gene expres-
sion is limited [8].
Initiation of viral replication from latency not only is
caused by immunosuppression but, like other viruses,
such as HIV [9], also appears to be linked to activation
of the immune system. For example, the virus can be
reactivated by tumor necrosis factor (TNF)- a,w h i c hi s
released during inflammation. TNF-a binds to the TNF
receptor on latently infected cells, generating signals
that activate nuclear factor-kB (NF-kB). Consequently,
the activated p65/p50 NF-kB heterodimer translocates
into the nucleus and binds to the IE enhancer region of
CMV, which initiates viral replication [10].
This molecular mechanism has a clinical correlate,
wherein the reactivation of latent CMV has been asso-
ciated with elevated serum levels of TNF-a in patients
with atopic dermatitis [11] and sepsis [10,12,13]. In
addition, CMV reactivates commonly following acute
rejection of organ transplants and after acute graft-ver-
sus-host disease (GVHD) in bone marrow transplant * Correspondence: stefania.varani@unibo.it
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[14-17].
Further, proinflammatory prostaglandins stimulate
cyclic AMP, which then triggers viral reactivation [18].
Stress catecholamines can induce increases in cyclic
AMP concentrations, leading to viral reactivation [6,19].
Through such mechanisms, chronic inflammation is
likely to mediate the reactivation of CMV.
Cells of the myeloid lineage are carriers of latent CMV
[20,21]. CMV can reactivate f r o ml a t e n c yb ya l l o g e n e i c
stimulation of monocytes from seropositive donors [22].
Viral reactivation also occurs when mononuclear hema-
topoietic progenitors that are latently infected with
CMV differentiate into mature DCs [23]. Thus, inflam-
mation and cellular differentiation are events that reacti-
vate CMV.
Clinical features of CMV infection and disease
CMV infection in immunocompetent hosts
In adults, primary CMV infection occurs in 0.1% to 0.6%
of blood donors and typically is prolonged [24,25].
Immunocompetent individuals with primary infections
are frequently asymptomatic [25,26], but CMV occasion-
ally effects clinical illness-i.e., a self-limited mononucleo-
sis-like syndrome. Clinically, the mononucleosis that is
caused by CMV is similar to the more common
Epstein-Barr virus (EBV) mononucleosis. Malaise, head-
ache, and high fever are hallmarks of CMV mononu-
cleosis and can persist for weeks. Other clinical
abnormalities have been associated with CMV infection
in normal hosts, including Guillain-Barré syndrome,
meningoencephalitis, hemolytic anemia, and thrombocy-
topenia [1].
CMV infection in immunocompromised patients
CMV infections are among the most common infections
that follow transplantation. In such transplant recipients,
CMV infection manifests as a wide range of conditions,
from asymptomatic viremia to CMV syndrome and tis-
sue-invasive disease [27].
CMV infection in immunocompromised individuals
causes disparate clinical syndromes in different groups
of patients, and the severity of infection is proportional
to the degree of immunosuppression. The most severe
infections develop in allogeneic bone marrow and allo-
geneic stem cell transplant (alloSCT) recipients and in
AIDS patients with low CD4
+ counts. Symptomatic
CMV infections are also observed often in solid organ
transplant recipients.
The effects of CMV infection in transplant patients
can be divided into 2 categories: direct effects of the
infection that cause mononucleosis-like syndrome or tis-
sue-invasive disease, and indirect effects [28-30]. CMV
tissue-invasive disease is suspected if high levels of
CMV viremia develop and is confirmed by detection of
the virus in the affected tissue by immunohistochemis-
try. The transplanted organ is the principal target of
CMV infection in solid organ recipients [30]. This is not
the case in BMT recipients, where CMV disease fre-
quently manifests as interstitial pneumonia [31].
CMV is also associated with indirect effects, a term
that encompasses the effects that are coupled to longer
periods of low viral replication and that are caused in
part by the host’s immune response. Such effects include
graft rejection and immunosuppression.
CMV infection in patients with autoimmune disorders
Recently, laboratory-based signs of active CMV infection
have been observed in association with the onset and
course of autoimmune diseases, as reviewed extensively
below.
The virus as an immunopathological agent:
autoimmunity, immunosuppression, and graft
rejection
A. Autoimmunity
A1. Induction of autoantibodies
Autoimmune phenomena often develop in CMV-
infected patients. For example, anti-phospholipid and
anti-CD13 autoantibodies have been observed in CMV-
infected BMT recipients [32-34], and anti-CD13 has
been linked to the development of chronic GVHD in
these patients [35]. In solid organ transplant recipients,
non-organ-specific autoantibodies, such as anti-endothe-
lial cell, anti-smooth muscle cell, and anti-nucleus anti-
bodies, are associated with CMV infection [36,37], likely
increasing the risk for humoral and chronic allograft
rejection [38,39]. In addition, hypergammaglobulinemia,
cryoglobulinemia, and autoantibody production are fea-
tures of CMV-induced mononucleosis and postperfusion
syndrome [40-42].
A2. Induction of vasculitides and scleroderma
T h et i m ec o u r s eo fa c t i v eC M Vi n f e c t i o na n dt h eo n s e t
of autoimmune disorders have been linked in previously
healthy individuals. Notably, the presence of CMV repli-
cation has been associated with the development of
autoimmune vasculitis and scleroderma, implicating
virus-induced vasculopathy as a trigger of autoimmunity.
In fact, active CMV infection has been correlated with
newly diagnosed necrotizing vasculitis [43], cutaneous
vasculitis [44], and systemic lupus erythematosus (SLE)-
associated vasculitis [45]. In all but one case, the symp-
toms improved with ganciclovir, in association or not
with prednisone.
Further, a previously healthy woman who acquired
CMV mononucleosis developed vasculitis with antineu-
trophil cytoplasmic antibodies (c-ANCA). This patient
had extraordinarily high plasma levels of IL-5 and
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tant with the primary CMV infection. After the onset of
vasculitis, CMV genomes were detected in the blood
and urine, and CMV antigens were observed in inflam-
matory lesions of the kidney, suggesting that CMV trig-
gers and maintains the autoimmune process [42].
Finally, CMV RNA was detected in endothelial cells
from skin biopsies in patients who presented with sud-
den onset of autoimmune sclerosis. One patient was
treated with ganciclovir, which did not improve the clin-
ical course of the disease [44].
A3. Induction of encephalitis associated with autoimmune
phenomena
Recently, a previously healthy woman who suffered from
active CMV experienced abrupt onset of encephalitis
that was associated with autoimmune phenomena. Pri-
mary CMV infection was diagnosed by serology, and
CMV DNA was detected in the cerebrospinal fluid and
blood at the onset of symptoms. Long-course treatment
with ganciclovir and intravenous immunoglobulins and
decreasing doses of cortisone improved the neurological
status. Although viral replication was halted and immu-
nosuppressive therapy was discontinued, extremely low
levels of CMV-specific CD4
+ and CD8
+ T cells were
detected for up to 10 months after disease onset. Con-
versely, high blood interferon (IFN)- g levels were
observed, suggesting enhancement of nonspecific
immune mechanisms that were activated to compensate
for the lack of CMV-specific T cell responses (Xu, Var-
ani et al., manuscript in preparation). This case suggests
that CMV infection in subjects with potentially hidden
immune defects can enhance viral replication that trig-
gers autoimmune phenomena.
Although it is possible that they are unrelated with
regard to causation, the concurrent active CMV infec-
tion and onset of autoimmunity that were observed in
these cases suggest that CMV induces autoimmunity in
predisposed individuals.
A4. Increased risk for post-transplant diabetes mellitus
Viral infections, such as enteroviruses and mumps virus,
are believed to provoke type I diabetes in genetically
predisposed individuals [46]. Clinical evidence suggests
that asymptomatic CMV infection and CMV disease are
independent risk factors for early-onset diabetes melli-
tus in recipients of renal transplant (generally referred
to as PTDM) [47,48]. Further, CMV donor-positive/
recipient-negative serostatus is a risk factor for the
development of PTDM in pediatric renal transplant
patients [49], and active CMV infection predisposes
adult liver transplant patients to the development of
PTDM [50]. The incidence of PTDM has declined sig-
nificantly since the introduction of preemptive anti-
CMV regimens, supporting the link between CMV and
PTDM [51].
CMV damages b-cells by direct viral infection (the
pancreas is a target organ of CMV infection [52]),
through the cytotoxic effects of activated effector lym-
phocyte infiltrates, or the induction of proinflammatory
cytokines [53]. There are limited experimental data on
the inhibition of b-cell function by CMV, however,
necessitating additional studies to demonstrate a causal
relationship between CMV infection and PTDM.
A5. Active infection during autoimmune disorders
Current findings suggest that latent CMV can be reacti-
vated by allogeneic stimulation in monocytes from sero-
p o s i t i v ed o n o r s[ 2 2 ]a n dt h a tI F N - g and TNF-a are
necessary for the differentiation of CMV-permissive
Mjs [54]. These findings have clinical implications,
because immune-mediated processes that involve T cell
activation and inflammation may facilitate the reactiva-
tion of latent CMV in monocytes in vivo. Thus, the
chronic inflammation that is associated with autoim-
mune diseases might provide the ideal microenviron-
ment in which latent CMV can be reactivated in Mjs;
this inflammation can induce DC maturation, which can
also provoke viral reactivation from latency [23].
Inflammatory bowel diseases and other enteropathies
CMV replicates efficiently in epithelial cells of the
intestinal mucosa [55,56] and is a major cause of graft
failure after intestinal transplantation [57]. In recent
years, many studies have focused on the pathogenic
function of CMV replication in inflammatory bowel dis-
ease (IBD). Notably, CMV antigens have been found in
10% to 90% of biopsies from patients with IBD [58-60].
Patients with inactive or mild to moderate ulcerative
colitis (UC) [60,61] and Crohn disease [60-63] rarely
show signs of CMV replication, whereas active CMV
infection exists in 20% to 40% of steroid-refractory UC
[63-73], suggesting that CMV exacerbates inflammation.
Antiviral treatment in patients with steroid-resistant
UC and active CMV infection has been efficacious in
isolated cases or small groups of patients
[63,65,68,70,71,74], whereas other studies have reported
clinical improvements in CMV colitis in the absence of
antiviral medication [60,75,76], indicating the need for
large, randomized, controlled studies to determine the
true clinical value of antivirals in CMV-positive UC.
Notably, active CMV infection was diagnosed based
on the detection of CMV in mucosal biopsy specimens
from the colon by immunohistochemistry and PCR in
the majority of these studies [60,63-66,68-70,72,77],
whereas blood analysis, when performed, demonstrated
low viral loads or the absence of viremia [63,64]. These
findings imply that CMV replication occurs primarily in
the colon of patients with UC.
Further, recent evidence has shown that all patients
with steroid-refractory UC who have experienced active
CMV infection have been previously CMV-seropositive,
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inflammation during the active phase of disease [63].
Latently infected monocytes [20] are recruited to the
site of colonic inflammation, where monocyte activation
and differentiation can induce viral reactivation [22,23].
Whether epithelial cells of the colonic mucosa carry
latent CMV that contributes to viral reactivation is
unknown.
Evidence indicates that CMV DNA can also be
detected in intestinal biopsies of patients with common
variable immunodeficiency (CVID) [78]. CVID is a het-
erogeneous disease that results in hypogammaglobuline-
mia, a propensity for infection and autoimmunity and
that may also complicate with severe enteropathy. The
role of CMV infection in triggering/worsening such dis-
ease is only partially understood; preliminary clinical
observations suggest that an exaggerated T cell response
to CMV may cause or exacerbate enteropathy in CVID
[79], further underscoring the potential inflammatory
role of CMV in the gastrointestinal tract.
Autoimmune disorders with major vascular involve-
ment: vasculitis and systemic sclerosis Increasing evi-
dence suggests that in addition to hepatitis C (HCV),
o t h e rv i r u s e s ,s u c ha sC M V ,E B V ,H I V ,a n dp a r v o v i r u s
B19, accompany systemic vasculitis [80]. In such disor-
ders, CMV infection coincides with the onset of inflam-
matory disease [42-45], as discussed, or with the
initiation of immunosuppressive therapy [81]. Recently,
IgM antibodies against CMV were observed more fre-
quently in patients with c-ANCA-positive vasculitis
compared with controls, while no other viral, bacterial
and parasitic infections appeared to be involved [82].
Thus, CMV infection might initiate or maintain inflam-
mation in vasculitides.
CMV has also been implicated as a trigger of vascular
damage in systemic sclerosis [83]. The clinical onset of
systemic sclerosis has been associated with the presence
of an active CMV infection [44]. Further, autoantibodies
that are specific for systemic sclerosis recognize the late
CMV protein UL94 and are associated with the diffuse
form of the disease but not the limited form, suggesting
a correlation between the virus and disease severity
[84,85]. Notably, antibodies against UL94 induce apop-
tosis in endothelial cells and activate dermal fibroblasts
in vitro, effecting 2 hallmarks of systemic sclerosis-vas-
cular damage and fibrosis [86].
Other autoimmune disorders Laboratory signs of acute
CMV infection and anti-CMV have been observed in
other autoimmune diseases. Subclinical systemic CMV
infection develops in psoriatic patients and is associated
with high levels of TNF-a [87]. Moreover, CMV DNA,
specific antigens, and infectious virus particles have been
detected in synovial tissue and fluid from the joints of 10%
to 50% patients with rheumatoid arthritis (RA) [88-91].
Active CMV infection is also frequent in children with
SLE [92], and CMV has been implicated in its develop-
ment and exacerbation [93-97]. Serological signs of
active CMV infection have been detected in 10% of
patients with SLE, and the presence of viral infection is
associated with higher disease activity scores [98].
Patients with SLE also have more robust humoral activ-
ity in response to CMV [99] and, in particular, to the
CMV structural protein pp65 [100] compared with
healthy donors and patients with other autoimmune dis-
orders. In a recent study, CMV was the only infectious
agent for which higher rates of IgM seropositivity and
higher antibody titers were observed in SLE patients
versus controls [101].
B. Immunosuppression
CMV infection (mainly primary infection) causes transi-
ent but substantial immunosuppression [102]. CMV
effects immunosuppression in solid organ transplant
recipients, potentiating superinfections with various
pathogens [103]. Notably, meta-analyses of thousands of
transplant recipients have demonstrated significant
effects of anti-CMV prophylaxis in preventing bacterial
and fungal [104] infections and bacterial and protozoan
[105] infections. Further, in solid organ recipients, CMV
replication influences the viral load of other viruses,
such as human herpes virus (HHV)-6 and HHV-7 [106],
and HCV load [107].
Owing to its immunosuppressive effect, CMV has also
been suggested as a risk factor for the development of
post-transplant lymphoproliferative disorders (PTLDs) in
solid organ recipients, a pathological condition that is
associated strictly with EBV replication [108]. In particular,
CMV mismatch (donor positive/recipient negative) [109]
and CMV disease [110] have been identified as general
risk factors predisposing to the development of PTLD in
solid organ transplant recipients. However, recent evi-
dence shows no correlation between CMV disease and the
development of PTLD [111-113]. Therefore, whether
CMV is associated to an increased risk of PTLD is debata-
ble and further studies are needed to clarify this matter.
CMV is immunosuppressive in allo-SCT recipients
and death appears to be mediated by invasive bacterial
and fungal infections, of which invasive aspergillosis is
the most significant complication [114]. In addition, by
preventing CMV replication in BMT recipients, a reduc-
tion in mortality as a result of all types of infections is
achieved [115]. Finally, an increased risk of death from
infections has been shown in CMV-seropositive BMT
recipients receiving grafts from seronegative donors
[114,116,117], supporting the importance of transferring
specific T cells with the graft to control CMV replica-
tion and its immunomodulatory effects in this patient’s
cohort.
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CMV promotes classical rejection and vasculopathy of
an allograft, which impacts its longevity [6]. Several
cohort studies have shown that CMV infection is asso-
ciated with an increased risk of graft rejection in renal,
liver, and lung transplant patients [118-121].
Studies in heart transplant recipients report that acute
rejection and accelerated coronary atherosclerosis are
linked to asymptomatic and symptomatic CMV infec-
tion [122,123]. Cardiac transplant vascular sclerosis,
characterized histologically by diffuse concentric intimal
proliferation that results in vessel stenosis and, ulti-
mately, allograft failure [124], is highly associated with
CMV in heart transplant recipients [125]. The higher
incidence of viral DNA in explant vascular intima from
patients with cardiac graft vascular sclerosis compared
with explants without vasculopathy underscores the
influence of CMV on the development of chronic rejec-
tion [126]. In addition, the early control of subclinical
replication of CMV after cardiac transplantation by T
cell immunity may reduce allograft vasculopathy and
allograft rejection [127].
Chronic vasculopathy has also been associated with
CMV in kidney transplant recipients [128]; bronchiolitis
obliterans in lung recipients also correlates with CMV
infection [119,129]. Several randomized trials of antiviral
prophylaxis and preemptive therapy have demonstrated
that antivirals provide significant protection against
CMV-associated allograft injury, providing the strongest
evidence for the link between CMV infection and allo-
graft rejection [104,130-133].
In BMT recipients, GVHD and CMV replication are
pathogenetically associated; multiple studies show that
GVHD and its treatment put patients at risk for CMV
replication [134-136]. In contrast, the role of CMV
replication as a cause of GVHD is controversial. Oppo-
site findings have been published on the effect of CMV
r e p l i c a t i o no nd e v e l o p m e n to fa c u t eG V H D
[116,136-139]. Several studies showed that an increased
risk of chronic GVHD was associated with CMV viremia
[35,137,140] and that BMT patients receiving pre-emp-
tive therapy for CMV replication exhibited lower risks
for severe chronic GVHD [141]. On the other hand,
large randomized studies of prophylaxis with acyclovir
or valacyclovir showing effects on CMV replication did
not have any impact on the risk for GVHD [115,142].
Mechanisms of CMV-induced immunopathology
A. Humoral autoimmunity
The mechanisms by which CMV interacts with the
immune response to induce autoimmune phenomena
are unknown. One possibility is viral mimicry [143]. The
CMV genome harbors a series of genes that are homo-
logous to cellular genes; consequently, the host response
to viral determinants can crossreact with host tissues,
leading to autoimmunity (Figure 1A). This mechanism
likely explains the generation of pathogenetic autoanti-
bodies that crossreact with CMV during systemic sclero-
sis [83].
Humoral autoimmunity can also be elicited by non-
specific B cell activation that is caused by CMV. CMV
is a polyclonal B-cell activator in vitro,a n dt h eBc e l l
hyperresponse does not require viral replication [144].
In addition, CMV interacts with toll-like receptor (TLR)
7 and/or 9 in human plasmacytoid DCs, leading to
secretion of IFN-a and B cell proliferation [145]. These
DC-mediated events might facilitate polyclonal B cell
activation and autoantibody production during CMV
infection (Figure 1A).
B cell hyperactivation has clinical implications for
infected patients, as demonstrated in transplant recipi-
ents, wherein autoantibodies contribute to the develop-
ment of GVHD in CMV-infected alloSCT patients and
to graft rejection in solid organ recipients [34,35,38,39].
B. Inflammation
Primary and latent CMV infections induce chronic, sys-
temic type 1 inflammatory responses [7]. Such sustained
immune activation can augment alloimmune responses
by enhancing the expansion and function of alloreactive
T cells after transplantation. Moreover, the protracted
elevation in serum IFN-g levels can increase major histo-
compatibility complex (MHC) expression on graft cells,
raising the risk of recognition by alloantigen-specific T
cells. Both mechanisms can mediate allograft rejection.
The primary involvement of IFN-g, T-bet (functional
markers of Th1 CD4
+ T cells), and granzyme B (a cyto-
toxic marker of CD8
+ cells) in the pathogenesis of trans-
plant glomerulopathy [146], a major risk factor for
chronic graft rejection, has been demonstrated recently,
implicating Th1-inducing CMV in chronic rejection in
renal transplant recipients. Immune-mediated damage,
involving CD8
+ granzyme
+ cytotoxic T cells, has also
been observed in fetuses that are severely affected by
congenital CMV infections (Gabrielli, Landini et al.,
manuscript in preparation). As discussed below, inflam-
mation might enhance autoimmunity when CMV has
reactivated in autoimmune diseases.
Generation of CD4
+ CD28
null T cells
Au n i q u es u b s e to fC D 4
+ T cells that lack the costimu-
latory molecule CD28 expand in patients with autoim-
mune diseases, such as RA, Wegener’s granulomatosis,
dermatomyositis and polymyositis, multiple sclerosis,
and IBD [147-150]. These cells have pathogenic proper-
ties in vitro [151], are a major source of Th1 cytokines
in lesions in Wegener’s granulomatosis [152], and are
associated with early atherosclerotic vessel damage in
RA patients [153]. In addition, CD4
+CD28
- and CD8
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- T cells are the predominant T cells that infil-
trate inflamed muscles in patients with dermatomyositis
and polymyositis, secreting IFN-g on CMV-specific anti-
genic stimulation [150].
Notably, CD4
+CD28
- T cells appear to exist almost
exclusively in CMV-infected individuals [150,154]. In
RA patients and healthy controls, CD4
+CD28
- lympho-
cytes react specifically with several CMV epitopes [151].
Thus, CMV replication in inflammatory lesions has
been speculated to drive the differentiation of CD4
+ T
cells into pathogenic CD28
null T cells, thereby aggravat-
ing local chronic inflammation in autoimmune disorders
[151] (Figure 1B).
NF-kB and other inflammatory factors
In addition to inducing the end-stage differentiation of
pathogenic T cells, CMV sustains chronic inflammation
through other mechanisms. In vitro, CMV infection sti-
mulates the translocation of NF-kB into the nucleus,
which then upregulates TNF-a, leading to further acti-
vation of latent CMV and inflammatory responses [155].
CMV induces transient cyclooxygenase 2 expression in
infected fibroblasts and the subsequent release of prosta-
glandin E2, a mediator of inflammation [156]. CMV also
stimulates 5-lypoxygenase expression, which is crucial
for the synthesis of leukotriene B4, a powerful chemoat-
tractant [157] (Figure 1B). In addition, CMV infects var-
ious subsets of myeloid antigen-presenting cells (APCs)
efficiently [158-160] that, once infected, release myriad
inflammatory mediators [160-162] (Figure 1B). These
mechanisms might sustain inflammation in CMV-
infected lesions in autoimmune disorders and CMV-
positive allografts.
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Viral infections mediate the pathogenesis of vascular
damage and vascular stenosis through various mechan-
isms, such as the infection of endothelial cells, causing
cellular dysfunction or death; immune-mediated injury
of the vessel wall; hemorheological dysfunction due to
increased procoagulant activity; and migration and pro-
liferation of smooth muscle cells [163-165].
CMV can productively infect endothelial cells in vitro
[166-168] and CMV-infected endothelial cells are dys-
functional, due to diminished expression and activity of
endothelial nitric oxide synthase [169]; augmented
release of IL-8, a regulator of neutrophil migration
[170]; increased secretion of the proinflammatory cyto-
kine IL-1b; and upregulation of adhesion molecules that
promote leukocyte adhesion [171] (Figure 1C).
The function of virus-induced cytokines and chemo-
kines in the initiation and exacerbation of vascular
damage is a growing area of research. CMV induces the
release of proinflammatory cytokines and chemokines
and encodes CC and CXC chemokine homologs that
recruit cellular infiltrates [165]. In addition, during host
CD4
+ T cell responses to CMV antigens, sufficient levels
of IFN-g and TNF-a are generated to induce the expres-
sion of fractalkine in endothelial cells [172]. On such
upregulation, fractalkine mediates the recruitment and
mobilization of natural killer (NK) cells and monocytes,
which damage endothelial cells [173]. Thus, CMV-asso-
ciated chronic endothelial cell inflammation and damage
result from chemokine-mediated immunopathogenic
effects (Figure 1C).
CMV infection can modulate the activity of the
endothelium-from anticoagulant to procoagulant [174]-
and induce platelet adherence and aggregation in
infected endothelium [175]. Such effects can aggravate
the vascular damage that is induced by CMV and induce
vascular inflammation (Figure 1C). Endothelial cell
damage, cytokine and chemokine release, and cellular
dysfunction likely contribute to allograft-associated vas-
culopathy [165].
In addition to endothelialc e l l s ,C M Vp r o d u c t i v e l y
infects all cell types that are involved in vascular rejec-
tion, including smooth muscle cells (SMCs), Mjs, and
fibroblasts. The migration of SMCs from the media into
the neointimal space and their subsequent proliferation
are hallmarks of the development of vascular lesions
during allograft vasculopathy.
C M Vb l o c k sa p o p t o s i st h r o u g hv a r i o u sm e c h a n i s m s
[176], which effects the accumulation of SMCs. CMV
also induces the production of potent stimuli of SMC
proliferation, such as platelet-derived growth factor
[177]. In addition, by generating the chemokine receptor
US28, CMV enhances SMC migration [178]. The result-
ing accumulation of SMCs in the vessel intima on CMV
infection leads to neointimal hyperplasia and vessel nar-
rowing. Activated inflammatory cells, fibroblasts, and
SMCs within vascular lesions are important local
sources of factors that promote angiogenesis [179],
which accelerates the development of transplant vascular
sclerosis (Figure 1C).
D. Immunosuppression
Because CMV induces a robust and chronic antigenic
response in immunocompetent individuals that increases
with age [180], it has evolved several mechanisms to
suppress and evade this response and persist in the
host. Such mechanisms lead to transient but substantial
immunosuppression against the virus itself and unre-
lated pathogens [181].
CMV-induced impairments that impede host immune
responses have been demonstrated in vivo and in vitro.
For example, patients with CMV mononucleosis experi-
ence a loss in delayed-type hypersensitivity reactions to
recall antigens [182] and reduced lymphoproliferative
responses to mitogens [183] and specific antigens [184].
In immunocompetent adolescents with asymptomatic
primary CMV infections, lymphocyte proliferation in
r e s p o n s et oC M Vi sl e s sr o b u s tt h a ni ns e r o p o s i t i v e
controls [26]. Specific cell-mediated immunity is also
attenuated in children with congenital [185] and
acquired [186] CMV infections.
In vitro, CMV suppresses lymphocyte proliferation to
T cell mitogens and prevents lymphocytes and mono-
cytes from producing and responding to immune media-
tors, such as IL-1 and IL-2 [187]. In addition, CMV
inhibits cytotoxic and NK cell activity [188,189]. CMV
suppresses bone marrow myelopoiesis by infecting
hematopoietic progenitors and their progeny directly or
infecting stromal cells and altering the bone marrow
microenvironment [190-192].
These observations are supported by evidence of
impaired APC function on infection with CMV, includ-
ing altered phagocytosis, differentiation, migration and
maturation, and reduced expression of MHC molecules,
preventing effective antigen presentation to T cells
[160,162,187,193-199]. CMV impairs the ability of plas-
macytoid DCs to induce allogeneic T cell proliferation
[145], indicating broad virus-induced inhibition of var-
ious APC subsets.
The secretion of cmvIL-10 during CMV infection might
aid the virus in infecting and inhibiting DCs chronically
[200,201] (Figure 1D). CMV might use these mechanisms
as immunoevasive strategies and simultaneously effect
robust and broad inhibition of host immunity.
Treatment of virus-induced immunopathology
Despite the substantial progress in transplantology, CMV
continues to be a significant cause of morbidity in
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effects. While the direct effects of CMV infection are well
managed by treatment with ganciclovir or its prodrug, val-
ganciclovir, the optimal therapy for treating and prevent-
ing virus-induced immunopathology remains undefined
[6]. Studies indicate that antiviral prophylaxis provides sig-
nificant protection against CMV-associated allograft injury
and immunosuppression [104,105,130,131]. However, no
guidelines on the treatment of virus-induced immuno-
pathology in transplant recipients exist. Similarly, little is
known about the treatment of viral immunomodulation in
patients with autoimmune disorders.
When CMV replication is detected in patients with
autoimmune diseases, clinicians are faced with a thera-
peutic dilemma: should antiviral therapy be initiated and
immunosuppression be reduced to generate specific
antiviral immune responses, despite the risk of exacer-
bating the autoimmune disorder? Or, should the doses
of immunosuppressive agents be increased to suppress
inflammatory activity? Similarly, the treatment of CMV
infection that accompanies allograft rejection in solid
organ transplant recipients is complicated, because the
modulation of iatrogenic immunosuppression can oppo-
sitely influence CMV replication and the rejection epi-
sode [202].
As discussed, in 5 patients with vasculitis who tested
positive for active CMV infection, remission of the auto-
immunity was achieved on treatment with ganciclovir
alone or with CMV immunoglobulin and/or cortisone
[43-45]. We also effected a successful outcome in a
patient who developed encephalitis and autoimmune
phenomena on primary CMV infection after a long-
course treatment with ganciclovir and intravenous
immunoglobulins and decreasing doses of prednisone
(Xu, Varani et al., manuscript in preparation). The posi-
tive outcomes in these cases suggest that a 2-pronged
approach-comprising the inhibition of viral replication
by antivirals and immunomodulation by intravenous
IgG [203] and/or prednisone-is warranted when the
onset of autoimmune disorders coincides with active
CMV infection.
Increasing evidence shows that CMV exacerbates the
clinical outcome of UC, prompting the hypothesis that
antiviral therapy or another regimen that impedes viral
replication is beneficial when CMV infection is histolo-
gically proven at the site of inflammation [63]. To this
end, 3 therapeutic options have been considered; 1.
administration of antiviral compounds, 2. modulation of
immunosuppression, and 3. modulation of inflammation.
Many studies have reported successful outcomes using
antivirals, such as ganciclovir and oral valganciclovir, in iso-
lated cases or small groups of patients with steroid-refrac-
tory UC and active CMV infection [63,65,68,70,71,74].
Recently, it has been suggested that all UC patients with
severe colitis that is refractory to immunosuppressants be
tested for CMV reactivation and receive antiviral therapy if
colonic CMV is detected [204].
Modulating immunosuppressive therapy elicits stron-
ger anti-CMV immune responses; this option has been
used successfully alone [64] or with antivirals [64,67,71].
Because CMV reactivation depends strictly on inflam-
mation [10], treatments that reduce colonic inflamma-
tion, such as anti-TNF-a compounds and leukapheresis,
can reduce viral replication in UC patients, as shown by
2 recent reports [74,205].
Thus, the use of antivirals and indirect suppression of
viral replication might be effective treatments for CMV-
positive refractory UC. However, large, randomized,
controlled studies are needed to determine their effica-
cies in UC patients and other patients with autoimmune
disorders who experience active CMV infection.
Conclusion
During acute CMV infection, patients often suffer from
immunological dysfunctions. Autoimmune phenomena
are common in CMV-infected patients, and various
autoantibodies have been detected in patients with sys-
temic CMV infection [32-34,36,37,42]. Nonspecific
hyperactivation of humoral immunity can impede the
development of specific B cell responses-a potential
mechanism of viral immune evasion. Such a phenom-
enon has clinical implications for infected patients, as
demonstrated in transplant recipients-autoantibodies
mediate the development of GVHD in CMV-infected
alloSCT patients and graft rejection in solid organ reci-
pients [34,35,38,39] (Figure 2).
In potentially predisposed patients, primary CMV
infections can trigger autoimmune disorders, and vascu-
litides and scleroderma develop concomitantly with or
immediately after active CMV infection in previously
healthy, immunocompetent subjects [42-45]. In addition
to acute systemic CMV infection, low-grade CMV repli-
cation appears to be a frequent event in autoimmune
disorders [206]. CMV can accelerate the progression of
autoimmune disorders by mimicking autoimmune-
mediated tissue destruction and aggravating inflamma-
tion. Local viral replication is also associated with
chronic perivascular inflammation in solid organ trans-
plant recipients (Figure 2). In these patients, CMV per-
sists in the allograft, but few cells are infected directly
by CMV. These findings contrast the global effects that
CMV has on the acceleration of vascular stenosis and
chronic rejection, suggesting that CMV does not pro-
mote vascular disease through direct infection of vessels;
instead, it likely acts by indirect mechanisms that in
part involve the immune system [179].
Paradoxically, CMV infection, principally primary infec-
tion, induces transient but significant immunosuppression,
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infection in transplant recipients; such patients
develop increased risk for opportunistic infections that can
be reduced significantly by antiviral prophylaxis
[103-105,114] (Figure 2).
Herpesviruses are archetypal persistent infectious
agents that, even in individuals with essentially normal
immunity, escape occasionally from normal immune
control and cause symptomatic disease. Of all herpes-
viruses, CMV harbors the most genes that are com-
mitted to altering innate and adaptive host immunity
[4], and a significant fraction of the T cell repertoire in
CMV carriers is directed against this virus [1]. Because
CMV persists in the host, it can be erroneously impli-
cated in the pathogenesis of various diseases despite its
lack of involvement. Nevertheless, examples of immuno-
pathology that are attributed to CMV continue to accu-
mulate, suggesting that this virus has critical
immunomodulatory functions.
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